[Fibromyalgia: a challenge for neuroscience]
- PMID: 12833238
[Fibromyalgia: a challenge for neuroscience]
Abstract
Aims: In this survey we present the most recent findings regarding the physiopathology and therapeutic guidelines of a disease we still know very little about: fibromyalgia. This disorder is characterized by a chronic process of generalized musculoskeletal pain accompanied by chronic fatigue, sleep disorders and, on many occasions, neuroendocrine disorders.
Development: Most research on the physiopathology of fibromyalgia points towards some kind of pain transmission disorder in the dorsal horn of the spinal cord. In chronic pain processes, a resonance effect is produced in the synapse of the dorsal horn and this gives rise to allodynia and hyperalgesia. From a biochemical point of view, glutamate and substance P receptors, as well as the main systems involved in the transmission of pain, serotonin and noradrenaline, seem to play a fundamental role. Patients with fibromyalgia have generally been seen to have lowered 5HT activity and an increase in substance P. In addition to these alterations in the perception of pain, serotonin could also be responsible for the frequently occurring sleep, hormone and neuropsychiatric disorders observed in these patients.
Conclusions: Nowadays fibromyalgia is still a challenge for modern medicine. Indeed, the neuroscientific community must design a basic scientific approach carried out at the patient s bedside in order to find pharmacological tools with which to relieve these symptoms. Of the extensive therapeutic arsenal that has been tested in these patients to date, classical antidepressants and serotonin and noradrenaline reuptake inhibitors, used in sub antidepressant doses, seem to be the most effective.
Similar articles
-
Fibromyalgia: an overview.Am J Med. 2009 Dec;122(12 Suppl):S3-S13. doi: 10.1016/j.amjmed.2009.09.006. Am J Med. 2009. PMID: 19962494 Review.
-
Fibromyalgia--pathways and neurotransmitters.Hum Psychopharmacol. 2009 Jun;24 Suppl 1:S11-7. doi: 10.1002/hup.1029. Hum Psychopharmacol. 2009. PMID: 19479906
-
A review of fibromyalgia.Am J Manag Care. 2004 Nov;10(11 Pt 1):794-800. Am J Manag Care. 2004. PMID: 15623268 Review.
-
Nonmedicinal treatments in primary fibromyalgia.Rheum Dis Clin North Am. 1989 Feb;15(1):73-90. Rheum Dis Clin North Am. 1989. PMID: 2644680 Review.
-
Neuroendocrine therapy of fibromyalgia syndrome: an update.Ann N Y Acad Sci. 2010 Apr;1193:91-7. doi: 10.1111/j.1749-6632.2009.05345.x. Ann N Y Acad Sci. 2010. PMID: 20398013 Review.
Cited by
-
Prevalence of fibromyalgia in premenopausal and postmenopausal women and its relation to climacteric symptoms.Prz Menopauzalny. 2014 Jun;13(3):169-73. doi: 10.5114/pm.2014.43819. Epub 2014 Jun 30. Prz Menopauzalny. 2014. PMID: 26327850 Free PMC article.
-
Risk factors for fibromyalgia: the role of violence against women.Clin Rheumatol. 2009 Jul;28(7):777-86. doi: 10.1007/s10067-009-1147-6. Epub 2009 Mar 10. Clin Rheumatol. 2009. PMID: 19277813
-
Influence of craniosacral therapy on anxiety, depression and quality of life in patients with fibromyalgia.Evid Based Complement Alternat Med. 2011;2011:178769. doi: 10.1093/ecam/nep125. Epub 2011 Jun 15. Evid Based Complement Alternat Med. 2011. PMID: 19729492 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical